Orchid Shares Slide 11 Percent on Earnings Restatement and Delisting Notice

Apr 07, 2006

NEW YORK, April 7 (GenomeWeb News) - Shares of Orchid Cellmark were down 11.21 percent, or $.60, at $4.75 in mid-afternoon trading after the company reported that it will restate its earnings for the second and third quarters of 2005, and that it has received a delisting warning from the Nasdaq exchange for failing to file a financial statement on time.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Main menu